Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...

Amino acids play a fundamental role in regulating how cells respond to drugs. These molecules, which form proteins, act like ...

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

A team of NYU chemists and physicists are using cutting-edge tools—holographic microscopy and super-resolution imaging—to unlock how cells build and grow tiny, dynamic droplets known as biomolecular ...

Psychiatric conditions, although less common than heart or metabolic issues, most strongly predict unfavourable outcomes in autoimmune encephalitis.

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the anti-diabetic medication.